AAAmira Al‐Uzri

Amira Al‐Uzri

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Amira Al‐Uzri has a total of 113 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Population Pharmacokinetics and Dosing Simulations of Pentobarbital in the Pediatric Population

    by Victoria Etges Helfer, Lorena Medina-Aymerich, William J. Muller, Marisa Meyer Do, Mcr Amira Al-Uzri Md, Russell McCulloh, Chi D. Hornik, PhD Stephen J. Balevic MD, Mb Rachel G. Greenberg Md, Daniel K. Benjamin Jr., et al.

    Pentobarbital is a barbiturate with sedative and anticonvulsant properties, occasionally used in pediatric patients for preoperative sedation, deep sedation during mechanical ventilation, and seizure control. Despite its long‐standing clinical use, age‐appropriate dosing remains challenging due to variability across studies and limited pediatric pharmacokinetic (PK) data. This study (NCT01431326) aimed to characterize the population pharmacokinetics of pentobarbital in pediatric patients (birth to 21 years) and evaluate dosing strategies using model‐based simulations. A two‐compartment population PK model, allometrically scaled to total body weight, adequately described pentobarbital plasma concentrations, with no additional covariates identified as significant. Simulations were conducted across four age groups: 1 to <2 years, 2 to <6 years, 6 to <12 years, and 12 to <18 years. Comparable exposures were achieved across groups, although older and heavier patients tended to exhibit slightly higher exposures when non‐capped doses were applied. Based on simulation results, intravenous bolus doses of 1 mg/kg for preoperative sedation and 5 mg/kg followed by a continuous infusion of 1 mg/kg/h for seizure management appeared appropriate across the evaluated age range. For deep sedation, lower infusion rates (0.75 mg/kg/h) may be sufficient in older children (6 to 18 years) to match exposures observed in younger patients (1 to 6 years old) receiving 1 mg/kg/h. These findings support the currently recommended dosing regimens for pentobarbital in pediatric patients aged 1 to <18 years.

  • Population Pharmacokinetics and Exposure‐Safety Analysis of Furosemide in Preterm Infants

    by Rachel L. Randell, Anil Maharaj, Matthew Laughon, Chi D. Hornik, Rachel G. Greenberg, Jason E. Lang, Michael Cohen‐Wolkowiez, Christoph P. Hornik, Ravinder Anand, Karen Martz, et al.

    Furosemide is the most commonly used diuretic in preterm infants despite an incompletely understood relationship between dosing, exposure, and safety within this population. The goals of this study were to characterize furosemide population pharmacokinetics (popPK) in preterm infants and to evaluate safety by relating simulated furosemide exposure to events of ototoxicity, nephrocalcinosis, and nephrolithiasis. A total of 146 plasma furosemide concentrations from 51 preterm (23‐28.9 weeks’ gestational age) infants across two studies (one randomized, placebo‐controlled, dose‐escalating safety trial and one opportunistic, observational study) were included in the analysis. Standard nonlinear mixed effects popPK modeling techniques were applied. Exposure was simulated using the final popPK model (area under the curve) and Monte Carlo simulations (maximum concentration [C max ]). Logistic regression was used to evaluate the relationship between exposure and safety events. The final popPK model was a one‐compartment model with the covariates of weight on volume of distribution and both weight and post‐natal age on clearance. The model showed accurate predictions, adequate precision, and good model fit. Simulations indicated that furosemide 2 mg/kg administered enterally every 6 h would result in few (approximately 4%) C max values exceeding a 50 µg/mL threshold reported to be associated with treatment‐associated ototoxicity, and no more than 1% for all other dosing regimens. Events of hearing loss, nephrocalcinosis, or nephrolithiasis were rare and showed no relationship with furosemide exposure in logistic regression analysis. These data contributed to the October 2024 FDA label update to include pediatric popPK data and improve dosing in preterm infants.


  • Open Access

    Correction: Population Pharmacokinetic Modeling of Oxcarbazepine and Its Active Metabolite 10‑Monohydroxy Derivative to Inform Dosing in Children with Obesity

    by Jaydeep Sinha, Kanecia Zimmerman, Stephen J. Balevic, Chi Hornik, William J. Muller, Mobeen Rathore, Marisa Meyer, Yaron Finkelstein, Amira Al-Uzri, Arpita Lakhotia, et al.

  • Open Access

    Population Pharmacokinetic Modeling of Oxcarbazepine and Its Active Metabolite 10-Monohydroxy Derivative to Inform Dosing in Children with Obesity

    by Jaydeep Sinha, Kanecia Zimmerman, Stephen J. Balevic, Chi Hornik, William J. Muller, Mobeen Rathore, Marisa Meyer, Yaron Finkelstein, Amira Al-Uzri, Arpita Lakhotia, et al.

    Background Oxcarbazepine (OXZ) is an antiepileptic drug whose pharmacological effect is primarily mediated by its active metabolite, 10-monohydroxy derivative (MHD). OXZ is approved for use in adults and children older than 2 years with an age- and body weight-tiered dosing recommendation, but dosing guidance for children with obesity is lacking. Objective This work aimed to assess the dosing requirements of OXZ in children with obesity to support label extension. Methods Two multicenter studies (NCT01431326 and NCT02993861) were conducted in patients receiving standard-of-care OXZ therapy. Participants ≥ 2 years of age with a body mass index ≥ 95th percentile were classified as obese. Plasma concentrations were measured by a validated liquid chromatography tandem mass spectrometry (LC-MS/MS) assay. Nonlinear mixed effects modeling was performed using NONMEM 7.4 to characterize the population pharmacokinetics of OXZ and MHD simultaneously. Simulations were performed to compare MHD systemic exposure in children ≥ 2 years of age with and without obesity. Results One hundred study participants with a median (range) age of 9 years (44 days–20.90 years) contributed 425 plasma concentrations of OXZ (n = 212) and MHD (n = 213). Fifty-two percent of the participants had obesity. A one-compartment joint parent–metabolite model with linear input–output and bi-directional transformation between OXZ and MHD best characterized the pharmacokinetics. Body size was the only covariate affecting pharmacokinetics, and a fat-free mass–based metric termed pharmacokinetic weight (PKWT) best characterized that effect allometrically. Simulation results revealed that the current dosing regimen of OXZ can produce comparable exposure of MHD in children ≥ 2 years of age with and without obesity. Conclusion A model-informed analysis confirms that the current pediatric dosing regimen of OXZ applies to children in general, regardless of their obesity status.


  • Population Pharmacokinetics of Alfentanil in Children

    by Lorena Medina‐Aymerich, Ngoc (Betty) Ngo, Daniel Gonzalez, Chi D. Hornik, Amira Al‐Uzri, Rachel G. Greenberg, Sarah G. Anderson, Elizabeth H. Payne, Sitora Turdalieva, Stephen J. Balevic

    Alfentanil is an opioid analgesic and anesthetic agent used in surgical procedures. Despite its widespread use in children, the U.S. Food and Drug Administration label lacks specific dosing recommendations for those under 12 years. A population pharmacokinetic analysis was performed using NONMEM (v7.5) to characterize alfentanil's disposition in children. The study included 58 plasma concentrations from 42 patients who received intravenous alfentanil as part of usual care. Median age was 7.57 years (range: 0.33‐17.80) and median dosing was 12.5 mcg/kg (range: 4‐43). A one‐compartment model with first‐order elimination best described alfentanil's pharmacokinetics. Among body size measures, total body weight (WT) significantly influenced clearance (CL [L/h]) = 7.42 × (WT/70) 0.75 ) and volume of distribution (V [L]) = 12.6 × (WT/70)1). Inter‐individual variability decreased after the inclusion of WT, coefficients of variation were reduced from 104% to 58% and from 169% to 83%, for CL and V, respectively. The final model facilitated simulations to achieve target efficacious analgesic and anesthetic concentrations. For analgesia, an initial 10 mcg/kg bolus (for the first hour) followed by an 8 mcg/kg/h infusion (starting at 1 h) achieved the efficacious targeted concentrations (10‐100 ng/mL). For procedures that typically require minimal or moderate sedation, a 25 mcg/kg bolus followed by a 20 mcg/kg/h infusion (starting at 5 min) achieved the targeted concentrations (50‐200 ng/mL, depending on the procedure). These regimens should be prospectively evaluated to ensure their safety and confirm their efficacy. Overall, this study provides valuable insights into pharmacokinetics and dosing of alfentanil in children.


  • Open Access

    Physiologically Based and Population Pharmacokinetic Modeling of Midazolam in Children With Obesity Using Real‐World Data

    by Sean McCann, Victória E. Helfer, Stephen J. Balevic, William J. Muller, John N. van Den Anker, Amira Al‐Uzri, Marisa L. Meyer, Sarah G. Anderson, Sitora Turdalieva, Andrea N. Edginton, et al.

    Children represent a highly complex and variable population for treatment, including interindividual differences in drug dose–exposure. Midazolam has been used as a sedative for hospitalized children on‐ and off‐label; however, factors affecting interindividual variability (IIV) in observed clearance for this population are not fully understood and can result in extreme under‐ or overexposure. Obesity has been described as a significant influence on midazolam in adolescents, which could potentially alter drug exposure. The goal of this study was to use two modeling strategies to evaluate dose–exposure of midazolam in children with and without obesity. Population pharmacokinetic modeling assessed whether measures of obesity status would explain some of the observed IIV for midazolam clearance. In all, 164 plasma concentrations were collected from 93 participating children, many with obesity. Covariate modeling did not identify any factors influential to clearance beyond body weight. Model IIV was similar to that observed in previous models of critically ill children (coefficient of variation, 175%) along with considerable residual unexplained variability (50.4%). Then, a previously published virtual population of children with obesity was incorporated into an existing physiologically based pharmacokinetic model of midazolam in the open‐source PK‐Sim software. Dosing simulations for a subset of 46 participants demonstrated minor overpredictions in children with obesity compared to those without. Both models predicted a minor (< 20%) increase in exposure for children with obesity given the same weight‐based dose. This research demonstrates the use of population pharmacokinetics combined with physiologically based pharmacokinetic modeling to compare simulated exposures in children with and without obesity.


  • Expansion of a Pharmacokinetic Model for Diazepam to Characterize Real‐World IV and Oral Data in Children With and Without Obesity

    by Sean M. McCann, Jiali Wen, Stephen J. Balevic, William J. Muller, Amira Al‐Uzri, Chi D. Hornik, Marisa L. Meyer, Sarah G. Anderson, Elizabeth H. Payne, Sitora Turdalieva, et al.

    Diazepam is a benzodiazepine approved for use in adults and children. The label incorporates recommended dosing for status epilepticus in children. Published population pharmacokinetic (PK) modeling recommends an intravenous bolus dose of 0.2 mg/kg capped at 8 mg to reach the suggested target exposure of 200‐600 ng/mL at 10 min post dose in children up to 17 years of age. This model was developed for children generally without obesity based on IV data, and it is unclear how increased body weight may affect exposure or target attainment given capped dosing. Diazepam concentrations after IV or oral administration for 61 children aged 2.5 to 20.6 years were used to externally evaluate the model including the addition of fixed oral absorption parameters. Then, PK parameters were re‐estimated with the external population alone and again in combination with the original population. Re‐estimated parameters from the combined population were used to simulate recommended dosing for children with and without obesity. The external dataset included 88 plasma concentrations from 61 children (54 with obesity) receiving diazepam per standard of care. The external evaluation resulted in 34.5% of predicted values within 30% of the observed concentration. Parameter re‐estimation resulted in increased central volume of distribution (26% increase from a previous model), reduced peripheral volume of distribution and intercompartmental clearance, and similar clearance estimates. Simulations demonstrated that dosing caps may prevent children with obesity from reaching the suggested target exposure that is recommended for the treatment of status epilepticus. Further study is needed to evaluate the target exposure range in this population.


  • Internet use and health literacy among pediatric chronic kidney disease patients and their caregivers

    by Eleanor Bold, Kelsey L. Richardson, Amira Al-Uzri, Sarah F. Craven, Kira Clark, Kimberly Grzesek, Seiji Koike, Kurt A. Freeman

    Background: Management of pediatric chronic kidney disease (CKD) is complex for affected youth and their families. Treatment requires a high level of family engagement to successfully manage medical appointments, inpatient hospital stays, and daily medication regimens. Health literacy has been identified as a possible contributor to health inequities and unsuccessful chronic disease management. This study sought to explore the perceived health literacy, health-related internet use, and provider trust of children with CKD and their caregivers compared to those without chronic health conditions to inform clinical care. Methods: Caregivers and children completed self-report surveys during routine specialty nephrology and general pediatrics clinic visits. In total, 85 caregivers and 46 youth participated. Statistical analyses included exploration of distributional properties, population differences, and group differences based on self-reported perceived health literacy. Results: Caregiver demographics did not significantly vary across samples. Patient demographics varied significantly across samples with regard to ethnicity. Internet use to find health information was low across samples, and caregivers of children without chronic health conditions endorsed significantly higher perceived health literacy compared to caregivers of children with CKD. Conclusions: Implications for practice include consideration of health literacy when treating children with CKD and patient preparedness for transition to adult care. Graphical


  • Trichodysplasia spinulosa mimicking lichen nitidus in a renal transplant patient

    by Hope Barone, Ross Brockman, Luke Johnson, Amira Al‐Uzri, Mary Wright, Stephanie Mengden‐Koon, Tracy Funk

    Trichodysplasia spinulosa (TS) is a rare cutaneous condition associated with the TSPyV and characterized by skin‐colored, folliculocentric papules with keratin spicule formation. TS is seen almost exclusively in immunosuppressed individuals, often presenting in patients with a history of solid organ transplantation or chemotherapy for a lymphoreticular malignancy. We report a case of widespread TS in a 9‐year‐old girl with a history of renal transplantation complicated by BK viremia, which is also caused by a polyomavirus, BKPyV. The clinical presentation of TS in this case morphologically resembled the more common, harmless skin condition known as “lichen nitidus,” and was more extensive than expected for TS, creating a diagnostic challenge. This case illustrates an important presentation of severe TS of which transplant teams, oncologists, primary care providers, and dermatologists should be aware.


  • Longitudinal study on the use of dried blood spots for home monitoring in children after kidney transplantation

    by A. Al‐Uzri, K. A. Freeman, Jordan Wade, K. Clark, L. A. Bleyle, M. Munar, D. R. Koop

    The use of DBSs for home monitoring has been limited due to unsatisfactory blood sampling and analytical difficulties. The aim of this longitudinal feasibility trial was to assess the utility of DBS to monitor TAC and Cr at home in transplant recipients. A total of 30 participants (2‐21 years, mean±SD, 13.6±5.4 year) were enrolled over 12 months. Eighteen were males. Monthly DBS samples were obtained at home and mailed to the central laboratory for analysis of TAC and Cr. Nineteen patients completed the study, and 216 cards were received in the laboratory from a total of 279 cards expected, with 416/519 (80%) blood spots being suitable for analysis. We found a high correlation between blood TAC and Cr levels by DBS and the clinical laboratory, R2=.81 and .95, respectively. Fifteen parents and 15 youth completed measures of satisfaction with and preference for DBS testing. All but one parent/caregiver and youth reported satisfaction and preference for this method of testing over laboratory blood draws. We conclude that home DBS monitoring is a feasible method to monitor TAC and Cr in pediatric transplant recipients.